SCHEMBL264880

SCHEMBL264880

Cc1c(N)nc(Nc2ccc(OCCN3CCCC3)cc2)nc1-c1cccc(N(C)C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 5/20 0.52
BACE1 P56817 5/20 0.52
SRC P12931 11/20 0.51
JAK2 O60674 2/20 0.51
JAK3 P52333 2/20 0.51
PTK2 Q05397 2/20 0.51
YES1 P07947 3/20 0.51
KDR P35968 3/20 0.51
EPHB4 P54760 3/20 0.51
PDGFRB P09619 3/20 0.51
ABL1 P00519 2/20 0.51
LCK P06239 2/20 0.51
LYN P07948 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C19 P33261 2/20 0.51
EGFR P00533 1/20 0.51
RAF1 P04049 1/20 0.51
FYN P06241 1/20 0.51
FGFR1 P11362 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264617 0.88 AXL (0.57) AXLBACE1SRCJAK2JAK3
SCHEMBL4515581 0.84 SRC (0.53) AXLBACE1SRCYES1KDR
SCHEMBL264327 0.83 AXL (0.62) AXLBACE1SRCYES1KDR
SCHEMBL264049 0.82 AXL (0.58) AXLBACE1SRCYES1KDR
SCHEMBL264602 0.81 KCNH2 (0.52) AXLBACE1SRCYES1KDR
SCHEMBL265091 0.81 AXL (0.64) AXLBACE1SRCYES1KDR
SCHEMBL265396 0.80 AXL (0.51) AXLBACE1SRCYES1KDR
SCHEMBL263711 0.80 AXL (0.57) AXLBACE1SRCYES1KDR
SCHEMBL263807 0.80 AXL (0.59) AXLBACE1SRCJAK2JAK3
SCHEMBL13032493 0.78 JAK2 (0.77) AXLBACE1SRCJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 US disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 US disclosed
US-7825246-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2010-11-02 US disclosed
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases TARGEGEN, INC. (US) 2009-11-19 US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, LTK AXL 376/4885BACE1 4487/4885SRC 73/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 AXL 267/4885BACE1 4739/4885SRC 80/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 AXL 267/4885BACE1 4739/4885SRC 80/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 AXL 267/4885BACE1 4739/4885SRC 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.